Astellas Pharma Inc. (Astellas) (TSE: 4503), a Japan-based pharmaceutical company, announced on Monday that it has entered into an Asset Purchase Agreement with Sandoz AG, a Swiss-based global company involved in generic pharmaceuticals and biosimilars.
Under the Asset Purchase Agreement, Astellas is to transfer the global product rights for antifungal agent MYCAMINE (micafungin sodium/product name in Japan: FUNGUARD). The contract is part of the company's ongoing efforts to optimise the allocation of management resources to accommodate the rapidly changing business environment and achieve sustainable growth.
A payment of USD62.5m to USD75m will be received upfront, depending on the date of the closing of the transaction, and potential sales-based milestone payments. Financial terms of the contract will be reported as a gain on divestiture of intangible assets.
Sandoz is to acquire the rights to sell MYCAMINE worldwide when the deal is completed.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US